McGuire Investment Group LLC boosted its holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Free Report) by 3.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 58,109 shares of the company’s stock after purchasing an additional 1,940 shares during the quarter. McGuire Investment Group LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $564,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Oxinas Partners Wealth Management LLC purchased a new position in Global X Genomics & Biotechnology ETF in the 4th quarter worth about $103,000. Atria Investments Inc purchased a new position in Global X Genomics & Biotechnology ETF in the 3rd quarter worth about $122,000. Centaurus Financial Inc. purchased a new position in Global X Genomics & Biotechnology ETF in the 2nd quarter worth about $146,000. Rockefeller Capital Management L.P. purchased a new position in Global X Genomics & Biotechnology ETF in the 3rd quarter worth about $205,000. Finally, James J. Burns & Company LLC increased its stake in Global X Genomics & Biotechnology ETF by 6.0% in the 3rd quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock worth $207,000 after purchasing an additional 1,038 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors.
Global X Genomics & Biotechnology ETF Price Performance
NASDAQ:GNOM opened at $10.18 on Friday. Global X Genomics & Biotechnology ETF has a fifty-two week low of $9.50 and a fifty-two week high of $12.53. The stock’s 50-day moving average is $10.14 and its two-hundred day moving average is $10.74. The stock has a market cap of $70.95 million, a PE ratio of -4.35 and a beta of 1.03.
Global X Genomics & Biotechnology ETF Company Profile
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
See Also
- Five stocks we like better than Global X Genomics & Biotechnology ETF
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Despite Short-Term Risks Freeport McMoran Worth a Look
Want to see what other hedge funds are holding GNOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Free Report).
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
